Volume 17, Issue 1 (4-2018)                   JRUMS 2018, 17(1): 53-62 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ghoreishi A, Mahmoodi M, Hajizadeh M, Sheykhfathollahi M, Shafipour M, Khoshdel A. The Comparison of Alpha 1- Antitrypsin Protein Activity in Type 1 Diabetic Patients Referred to the Rafsanjan Diabetes Center to Healthy Individuals in 2016. JRUMS 2018; 17 (1) :53-62
URL: http://journal.rums.ac.ir/article-1-3677-en.html
Rafsanjan University of Medical Sciences
Abstract:   (3715 Views)

Background and Objectives: Type 1 diabetes (diabetes mellitus) is a disease associated with metabolism. The most common form of type 1 diabetes is its autoimmune type. Alpha-1-antitrypsin (AAT) is a member of the serine protease inhibitors family and its role is to protect tissue degradation by protease. Hence, its defect or deficiency significantly increases the risk of various diseases. This study aimed to compare the activity of alpha-1 antitrypsin protein in patients with type 1 diabetes with healthy individuals.
Materials and Methods: This descriptive study carried out on 42 patients with type 1 diabetes between the ages of 18-28 years old who  referred to the Diabetes Clinic in the city of Rafsanjan in 2015. Healthy people were chosen among native male and female students aged from 18 to 28 years of Rafsanjan University of Medical Sciences who were matched for age and sex with the patients. AAT activity by trypsin inhibitory capacity (TIC) was  studied. For statistical analysis the chi-square test, t-test, and Pearson correlation coefficient were used.
Results: The amount of TIC in the patients with type 1 diabetes was 2.35 ±0.40 (μmol/min/ml) which was significantly lower than the amount in the healthy individuals that was 3.36 ±0.36 (μmol/min/ml) (P-value<0.001).
Conclusion: The results of this study revealed that AAT activity in the patients with type 1 diabetes was lower than  the healthy individuals. Therefore, it can be stated that AAT can be introduced as a potential target for treatment of type 1 diabetes.
Key word: Type 1 diabetes, Alpha-1 Antitrypsin, Trypsin Inhibitory Capacity
 
Funding: This research was funded by Rafsanjan University of Medical Sciences.
Conflict of interest: None declared.
Ethical approval: The Ethics Committee of Rafsanjan University of Medical Sciences approved the study.
 
How to cite this article: Ghoreishi A.S., Mahmoodi  M, Hajizade M.R, Sheykhfatollahi M, Shafipour M.R., Khoshdel A.R. The Comparison of Alpha 1- Antitrypsin Protein Activity in Type 1 Diabetic Patients Referred to the Rafsanjan Diabetes Center to Healthy Individuals in 2016. J Rafsanjan Univ Med Sci 2018; 16(11): 53-62. [Farsi]
 

Full-Text [PDF 297 kb]   (1429 Downloads) |   |   Full-Text (HTML)  (2285 Views)  
Type of Study: Research | Subject: Biochemistry
Received: 2017/02/2 | Accepted: 2018/02/5 | Published: 2018/04/28

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Journal of Rafsanjan University of Medical Sciences

Designed & Developed by : Yektaweb